Abstract A040: Gene and protein expression of MAGE, PD-L1, and associated immune landscape elements in non-small cell lung carcinoma (NSCLC), urothelial carcinoma (UC), squamous cell cancer of the head and neck (SCCHN), and cervical carcinoma (CC)
Stephanie H. Astrow,Izak Faiena,Rajul Jain,Alexandra Drakaki,Wesley S. Chang,Clark C. Fjeld,Jin Li,Adrian Bot
DOI: https://doi.org/10.1158/1535-7163.targ-17-a040
2018-01-01
Biomarkers
Abstract:Abstract Purpose: Therapeutic options are limited for patients with advanced solid tumors failing conventional chemotherapy. Clinical responses have been observed with adoptively transferred tumor-specific T cells, including a T-cell receptor (TCR)-based therapy targeting the Cancer Testis Antigens MAGE-A3 and MAGE-A6 (Lu et al., J Immunother Cancer 2015;3(Suppl 2) P158). A T-cell product comprising this TCR is currently being tested in a novel phase 1 multicenter trial (NCT03139370). The programmed cell death-1/programmed cell death ligand 1 (PD-1/PD-L1) pathway may interfere with antitumor immune mechanisms. Several inhibitors of PD-1/PD-L1 signaling have shown activity and acceptable safety in multiple advanced cancer histologies. The expression of MAGE A antigens is prevalent in diverse solid tumors (Kerkar et al., J Immunother 2016;39(4):181-7). The prevalence of MAGE A3/A6 expression among MAGE A-positive tumors, and the rate and pattern of PD-L1 expression in relation to MAGE expression, are of interest as they may create a rationale for MAGE A3/A6 directed TCR therapy, alone or in conjunction with PD1/PD-L1 inhibition. Here, we describe the development and analytical validation of a two-part assay system combining immunohistochemistry (IHC) and reverse-transcription quantitative polymerase chain reaction (RT-qPCR) for the detection of MAGE A3/A6 expression, and examine its performance in NSCLC, UC, SCCHN and CC. We also assess the coexpression of PD-L1 and other immune-related genes (e.g., HLAs) in tumor cells and/or immune cells to better understand the tumor microenvironment. Methods: Sections from approximately 200 formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens were screened by IHC for MAGE-A (mAb 6C1; recognizes MAGE A1, A2, A3, A4, A6, A10, A12) and PD-L1 (mAb E1L3N) expression. Gene expression analyses (RT-qPCR and RNA sequencing) were carried out on RNA extracted from adjacent tissue sections. Results: Analytical validation of the MAGE A3/A6 assay system successfully met predefined acceptance criteria appropriate for clinical sample testing. 75-80% of MAGE A IHC+ tumors were positive for MAGE A3/A6 mRNA. The rate of PD-L1 expression in tumor cells and/or immune cells in MAGE+ tumors was 89% for NSCLC (n=37), 41% for UC (n=32), 95% for SCCHN (n=19), and 100% for CC (n=7). Distinct tumor cell staining patterns were identified including samples in which PD-L1 and MAGE-A staining overlapped extensively, partially, or were nearly mutually exclusive. In some tumors, diffuse PD-L1+ immune cells were observed in the tumor bed; in other samples, PD-L1+ immune cells appeared to surround the tumor bed, while others showed lack of PD-L1+ immune cells. Conclusions: The results support clinical evaluation of a MAGE A3/A6 TCR T-cell product across these major histologies. This two-part MAGE A3/A6 screening assay may reduce the potential for false-positive results obtained using the 6c1 IHC assay alone , and be useful in screening subjects for anti-MAGE A3/A6 T-cell therapy. While the significance of staining patterns remains to be determined, the presence of PD-L1 positive TC and IC in MAGE A3/A6+ tumors supports the concept of checkpoint blockade in combination with T-cell therapy to treat advanced solid tumors. Citation Format: Stephanie H. Astrow, Izak Faiena, Rajul Jain, Alexandra Drakaki, Wesley S. Chang, Clark C. Fjeld, Jin Li, Adrian Bot. Gene and protein expression of MAGE, PD-L1, and associated immune landscape elements in non-small cell lung carcinoma (NSCLC), urothelial carcinoma (UC), squamous cell cancer of the head and neck (SCCHN), and cervical carcinoma (CC) [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A040.
biotechnology & applied microbiology,toxicology